Conformationally restricted analogues of nicotine and anabasine

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 16, 1998, Pages 2173-2178

  Vernier, Jean Michel ^a   Holsenback, Heather ^a   Cosford, Nicholas D P ^a   Whitten, Jeffrey P ^a   Menzaghi, Frédérique ^a   Reid, Richard ^a   Rao, Tadimeti S ^a   Sacaan, Aida I ^a   Lloyd, G Kenneth ^a   Suto, Carla M ^a   Chavez Noriega, Laura E ^a   Washburn, Mark S ^a   Urrutia, Arturo ^a   McDonald, Ian A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABASINE; ANABASINE DERIVATIVE; CHOLINERGIC RECEPTOR; MECAMYLAMINE; MORPHINE; NICOTINE; NICOTINE DERIVATIVE; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DRUG CONFORMATION; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LEARNING; MEMORY; NONHUMAN; OOCYTE; ORAL DRUG ADMINISTRATION; PAIN; PARKINSON DISEASE; RAT; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION; TAIL FLICK TEST; XENOPUS LAEVIS;

ANABASINE; ANIMALS; ANTIPARKINSON AGENTS; CALCIUM; CELL LINE; CHOLINERGIC AGONISTS; DRUG DESIGN; HUMANS; MACROMOLECULAR SUBSTANCES; MOLECULAR CONFORMATION; NEURONS; NICOTINE; PARKINSON DISEASE, SECONDARY; PIPERIDINES; PYRIDINES; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

ANIMALIA; XENOPUS LAEVIS;

EID: 0032544153     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00394-1     Document Type: Article

References (23)

1. 1. (a) McDonald, I. A.; Cosford, N. P. D.; Vernier, J.-M. Annu. Rep. Med. Chem. 1995, 30, 41;
2. (b) McDonald, I. A.; Vernier, J.-M.; Cosford, N. P. D. Cur. Pharm. Design. 1996, 2, 357.
3. 2. (a) Newhouse, P. A.; Sunderland, T.; Tariot, P. N.; Blumhardt, C. L.; Weingartner, H.; Mellow, A.; Murphey, D. L. Psychopharmacology 1988, 95, 171;
4. (b) Sahakian, B.; Jones, G.; Levy, R.; Gray, J.; Warburton, D. Psychiatry 1989, 154, 797.
5. 3. (a) Fagerstrom, K. O.; Pomerlau, O.; Giordani, B.; Stelson, F. Psychopharmacology 1994, 116, 117;
6. (b) Prasad, C.; Ikegami, H.; Shimizu, I.; Onaivi, E. S. Life Sci. 1994, 54, 1169.
7. 4. Sanberg, P. R.; Silver, A. A.; Shytle, R. D.; Philipp, M. K.; Cahill, D. W.; Fogelson, H. M.; McConville, B. J. Pharmacol. Ther. 1997, 74, 21.
8. 5. Bannon, A. W.; Decker, M. W.; Holladay, M. W.; Curzon, P.; Donnelly-Roberts, D.; Puttfarcken, P. S.; Bitner, R. S.; Diaz, A.; Dickenson, A. H.; Porsolt, R. D.; Williams, M.; Arneric, S. P. Science 1998, 279, 77.
9. 6. Brioni, J. D.; Morgan, S. J.; O'Neil, A. B.; Sykora, T. M.; Postl, S. P.; Pan, J. B.; Sullivan, J. P.; Arneric, S. P. Med. Chem. Res. 1996, 487.
10. 7. Glassco, W.; Suchocki, J.; George, C.; Martin, B. R.; May, E. L. J. Med. Chem. 1993, 36, 3381.
11. 8. Chorvat, R. J.; Palmer, J. R.; Pappo, R. J. Org. Chem. 1978, 43, 966.
12. 9. Cordonnier, G.; Sliwa, H. J. Chem. Research (S) 1979, 124.
13. 10. Chavdarian, C. G.; Seeman, J. I.; Wooten, J. B. J. Org. Chem. 1983, 48, 492.
14. 11. Whitesell, J. K.; Whitesell, M. A. Synthesis 1983, 517.
15. 12. (a) Stauderman, K. A.; Mahaffy, L. S.; Akong, M.; Veliçelebi, G.; Chavez-Noriega, L. E.; Crona, J. H.; Jonhson, E. C.; Elliott, K. J.; Gillespie, A.; Reid, R. T.; Adams, P.; Harpold, M.M.; and Corey-Naeve, J. J. Pharmacol. Exp. Ther. 1998, 284, 777;
16. (b) Chavez-Noriega, L. E.; Zahl, A.; Mahaffy, L. S.; Crona, J. H.; Reid, R. T.; Adams, P.; Elliott, K. J.; Berckhan, K.; Stauderman, K. A.; Corey-Naeve, J. Soc. Neurosci Abstr. 1996, 22 1527.
17. 13. Chavez-Noriega, L. E.; Crona, J. H.; Washburn, M. S.; Urrutia, A.; Elliott, K. J.; Johnson, E. C. J. Pharmacol. Exp. Ther. 1997, 280, 346.
18. 14. Flynn, D. D.; Mash, D. C. J. Neurochem. 1986, 47, 1948.
19. 15. Sacaan, A. I.; Dunlop, J. L.; Lloyd, G. K. J. Pharmacol. Exp. Ther. 1995, 274, 224.
20. 16. Menzaghi, F.; Whelan, K. T; Risbrough, V. B.; Rao, T. S.; Lloyd, G. K. J. Pharmacol. Exp.Ther. 1996, 280, 384.
21. 17. Induction of turning in rats with unilateral 6-hydroxy dopamine lesions of the nigro-striatal dopamine pathway: Compound 2 was evaluated using the procedure described by Ungerstedt and Arbutknott, Brain Res. 1970, 24, 485. Thus, rats were injected with desmethylimipradine (25 mg/kg i.p.) approximately 30 minutes prior to 6-hydroxydopamine infusion into the substantia nigra, then allowed to stabilize for two weeks.
22. 18. Tail Flick Assay: The latency in the time that elapsed between stimulus application and tail flick in rats was evaluated according to the procedure described by D'Amour and Smith, J. Pharmacol. Exp. Ther. 1941, 72, 74.
23. 19. Passive Avoidance Model: Compound 2 was administered immediately after training in ratsfollowing the procedure described by Decker, M. W.; Majchrzak, M. J.; Arneric, S. P. Pharm. Biochem. Behav. 1993, 45, 571.